8-K: Paysign Reports Strong Q1 2024 Results with 30% Revenue Growth and 135% Adjusted EBITDA Increase

Paysign's first quarter of 2024 saw a significant 30% increase in revenue and a 135% jump in adjusted EBITDA, driven by strong performance in its patient affordability business.

Summary

• Paysign's total revenue for the first quarter of 2024 reached $13.2 million, a 30% increase compared to the same period in 2023.
• The company reported a net income of $309 thousand, or $0.01 per diluted share, a significant improvement from a net loss of $160 thousand in the first quarter of 2023.
• Adjusted EBITDA for the quarter was $1.7 million, a 135% increase from $720 thousand in the first quarter of 2023, with diluted adjusted EBITDA per share at $0.03.
• Plasma revenue increased by 11%, driven by a net increase of five plasma centers, bringing the total to 469.
• Pharma patient affordability revenue saw a remarkable 305% increase, with 10 new programs added, totaling 53 active programs.
• The company exited the quarter with $7.0 million in unrestricted cash and no debt.
• Gross dollar load volume increased by 13% and gross spend volume increased by 11% compared to the first quarter of 2023.
• Average revenue per plasma center per month was $7,414, a 5% increase from $7,066 in the same period last year.
• Patient affordability claim volume increased by 235% compared to the first quarter of 2023.

Sentiment

Score: 9

Explanation: The document presents a very positive outlook with strong financial results, significant growth in key areas, and confirmation of full-year guidance. The company's management expresses optimism, and the overall tone is highly encouraging for investors.

Positives

• The company experienced significant revenue growth of 30% year-over-year.
• Adjusted EBITDA saw a substantial increase of 135% year-over-year.
• The patient affordability business is a major growth driver, with a 305% revenue increase.
• Paysign achieved a net profit of $309 thousand, a turnaround from a net loss in the previous year.
• Gross profit margins improved to 52.6%, indicating increased profitability.
• The company maintains a strong cash position with $7.0 million in unrestricted cash and no debt.
• The company is confirming its full-year 2024 guidance for total revenues and adjusted EBITDA.
• The company added 5 net new plasma donation centers and 10 net new pharma patient affordability programs.

Negatives

• Cost of revenues increased by 23%, primarily due to increased cardholder activity and network expenses.
• Selling, general, and administrative expenses increased by 20%, driven by increased compensation and benefits.
• Depreciation and amortization expenses increased by 52% due to capitalized software development costs.
• Unrestricted cash decreased by $10 million due to the timing of receivables and payables in the patient affordability business and investments in fixed assets and capitalized software development.

Risks

• The company's growth rate may not be sustainable in future periods.
• A downturn in the economy could reduce the customer base and demand for products and services.
• The company operates in a highly regulated environment, which could lead to compliance issues.
• Data security breaches could expose the company to liability and litigation.
• Changes in laws, regulations, or industry standards could negatively impact the business.

Future Outlook

Paysign is confirming its full-year 2024 guidance for total revenues to be in the range of $54.5 million to $56.7 million and adjusted EBITDA to be in the range of $8.0 million to $9.0 million. The company expects total revenue to increase by approximately 27.5% over the second quarter of 2023 with pharma revenue accounting for approximately 18.0% of the total. They also expect adjusted EBITDA to increase 65.0% to 70.0% from the second quarter of 2023 with an adjusted EBITDA margin in the range of 13.5% to 14.0%.

Management Comments

• Mark Newcomer, President & CEO of Paysign, stated that the patient affordability business has been expanding rapidly, marking a significant 305% rise in revenue over the first quarter of 2023.
• Mark Newcomer also mentioned that they anticipate continued growth across all business units and are particularly optimistic about the future of their patient affordability business.
• Jeff Baker, Paysign CFO, stated that the first quarter financial results were solid across all metrics and confirmed the full-year guidance given in March.

Industry Context

Paysign's strong performance, particularly in the patient affordability sector, reflects a growing trend in the healthcare industry towards digital payment solutions and patient support programs. The company's focus on technology and integrated payment processing positions it well to capitalize on these trends.

Comparison to Industry Standards

• While specific competitor data isn't provided in this document, Paysign's 30% revenue growth and 135% adjusted EBITDA growth are strong indicators of outperformance compared to industry averages for payment processing and healthcare technology companies.
• Companies like Wex Inc. and Global Payments Inc. are in the broader payment processing space, but Paysign's focus on healthcare and patient affordability provides a unique niche.
• The 305% growth in pharma patient affordability revenue is particularly noteworthy, suggesting a strong competitive advantage in this specific market segment.
• The company's ability to increase average revenue per plasma center by 5% indicates effective management and market penetration in the plasma industry.

Stakeholder Impact

• Shareholders will likely view the results positively due to the strong revenue and profit growth.
• Employees may benefit from the company's growth and continued hiring.
• Customers will likely benefit from the company's expanding services and programs.
• Suppliers and creditors may see increased business opportunities with the company's growth.

Next Steps

• The company will hold a conference call to discuss the first quarter 2024 financial results.
• The company will continue to focus on growth in all business units, particularly the patient affordability business.
• The company will continue to explore profitable market opportunities and deliver long-term value to shareholders.

Key Dates

Keywords

Paysign, financial results, prepaid card programs, patient affordability, digital banking, payment processing, plasma, EBITDA, revenue, net income